ArticleInvestigative ophthalmology & visual science2025
Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose: Thymosin beta-4 (TB4) is a small peptide upregulated in injured tissues, playing roles in cell migration, angiogenesis, inflammation, and oxidative stress. Studies show TB4 significantly promotes corneal wound healing after injury, leading to a clinical trial (RGN-259), with full US Food and Drug Administration approval still pending. Current limitations to TB4-based therapies are a short half-life and high peptide synthesis costs, limiting large-scale applications. Here, we engineered a tandem thymosin beta-4 (tTB4) peptide with improved therapeutic potential and scalability for corneal wound repair. Methods: tTB4 was produced by fusing two TB4 monomers into a single polypeptide, creating dual G-actin binding domains. Binding activity was investigated using structural, in vitro, and in vivo studies. tTB4 and TB4 effects on cell viability and migration were assessed in human telomerase-immortalized corneal epithelial (hTCEpi) cells. Their efficacy in promoting corneal wound healing was tested in a murine alkali-induced corneal injury model. Results: Structural modeling revealed tTB4 has a mechanistic advantage in enhancing actin polymerization over TB4, as it can simultaneously bind and sequester two G-actin molecules, facilitating filament formation. In vitro, tTB4 promoted increased hTCEpi viability and migration compared to TB4. In vivo, tTB4 promoted corneal wound healing and reduced scarring with greater efficacy than TB4. Conclusions: The engineered tTB4 exhibited superior bioactivity and enhanced corneal wound-healing efficacy over TB4. Given that tTB4 can be produced by bacterial fermentation, synthesis is simplified and more cost-effective than TB4. Together, our data demonstrate the potential of tandem peptide engineering to improve regenerative peptide pharmacokinetics and therapeutic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.